4/A: Fennec Pharmaceuticals CEO Jeffrey Hackman Awarded Stock Options and Restricted Share Units
SEC Form 4/A Filing
CEO Jeffrey Hackman receives 75,000 restricted share units and options for 50,000 shares of Fennec Pharmaceuticals stock.
Summary
- Jeffrey Hackman, CEO of Fennec Pharmaceuticals, was awarded 75,000 restricted share units and options to purchase 50,000 shares on March 28, 2025.
- The restricted share units were granted pursuant to the company's 2020 Equity Incentive Plan.
- One-third of the restricted share units will be released from restriction starting March 28, 2026, with the remainder vesting monthly until February 29, 2028.
- The incentive stock options, also granted under the 2020 Equity Incentive Plan, have an exercise price of $6.50.
- These options also vest in a similar manner to the restricted share units, beginning March 28, 2026, and fully vesting by February 29, 2028.
- Following these transactions, Hackman directly owns 475,000 common shares and 525,000 stock options.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, suggesting confidence in the company's future performance. The vesting schedule promotes long-term alignment.
Positives
- The equity grants align the CEO's interests with those of the shareholders.
- The vesting schedule encourages long-term performance and retention.
Industry Context
Equity grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders. The vesting schedule is typical for such grants.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
- Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options and restricted stock units to incentivize their leadership teams.
- The vesting schedules described are typical, often spanning 2-4 years with monthly or quarterly vesting after an initial cliff period.
Stakeholder Impact
- The equity grants incentivize management to increase shareholder value.
- Employees may view the grants as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/28/2025 | Date of transaction: Grant of restricted share units and stock options. |
| 03/28/2026 | Vesting Commencement Date: One-third of the shares subject to the award and options may be exercised. |
| 02/29/2028 | Date when 100% of the total number of shares subject to the award and options shall be released from restriction/vested. |
| 03/28/2035 | Expiration date of the stock options. |
| 04/03/2025 | Date of original filing. |
Keywords
Fennec Pharmaceuticals, Jeffrey Hackman, restricted share units, stock options, equity incentive plan, beneficial ownership, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.